This inventor holds 2 USPTO granted patents and 4 published patent applications. Top assignees: Bial-Portela & Cª, S.a., Bial-Portela Ca & S.a.. Active years: 2021.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2021
Title: The Innovations of Patrício Soares Da Silva
Introduction
Patrício Soares Da Silva is a notable inventor based in S. Mamede do Coronado, Portugal. He has made significant contributions to the field of pharmaceutical sciences, particularly in the development of dopamine-β-hydroxylase inhibitors. With a total of 2 patents to his name, his work has the potential to impact therapeutic methods significantly.
Latest Patents
Patrício's latest patents include innovative compounds that serve as dopamine-β-hydroxylase inhibitors. The first patent focuses on compounds of Formula Ia, which are useful in therapy and include pharmaceutically acceptable salts or solvates. This invention also covers pharmaceutical compositions comprising these compounds and therapeutic methods of treatment utilizing them. The second patent addresses blood-brain barrier-penetrant dopamine-β-hydroxylase inhibitors, again detailing compounds and their therapeutic applications.
Career Highlights
Throughout his career, Patrício has worked with reputable companies such as Bial-Portela & Cª, S.A. His experience in these organizations has allowed him to refine his expertise in pharmaceutical innovation and contribute to the development of new therapeutic solutions.
Collaborations
Patrício has collaborated with notable professionals in his field, including Tino Rossi and Laszlo Erno Kiss. These collaborations have likely enriched his research and development efforts, fostering a creative environment for innovation.
Conclusion
Patrício Soares Da Silva exemplifies the spirit of innovation in the pharmaceutical industry. His contributions through his patents and collaborations highlight the importance of research in developing new therapeutic methods.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
